Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. - Wikidata - awgldk - TriplyDB

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

http://www.wikidata.org/entity/Q31100308

about

Anti-vascular endothelial growth factor for diabetic macular oedema Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy Updates on the Clinical Trials in Diabetic Macular Edema The clinical utility of aflibercept for diabetic macular edema A review of therapies for diabetic macular oedema and rationale for combination therapy Treatment of diabetic retinopathy: Recent advances and unresolved challenges Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Diabetic macular edema: Current management 2013 Cost-effectiveness of treatment of diabetic macular edema.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis Multicolor pattern scan laser for diabetic retinopathy with cataract.Revolution to a new standard treatment of diabetic macular edema Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Optimal treatment of diabetic retinopathy.Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.[Navigated retinal laser therapy].Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy Anti-vascular endothelial growth factor therapy for diabetic macular edema Evolving strategies in the management of diabetic retinopathy Anti-VEGF for the management of diabetic macular edema.Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema Laser-based strategies to treat diabetic macular edema: history and new promising therapies.Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor.Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY DURING VITREORETINAL SURGERY FOR DENSE VITREOUS HEMORRHAGE IN THE PIONEER STUDY.RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.Current intravitreal pharmacologic therapies for diabetic macular edema.Novel Therapies in Development for Diabetic Macular Edema.[Diabetic maculopathy].Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon's Capsule Triamcinolone Acetonide Injection.A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study).

P2860

Q24193083-6ED2B2C6-A129-41D9-AD89-096E8A1E8DB1 Q24658546-36C05F10-F542-4444-9693-5F6B6C39FE8C Q26765468-B707250E-9385-42AF-BCF5-90570473C088 Q26767100-5AB4F376-882B-41DD-95A8-93CC0134725B Q26783575-0C55F712-7206-4784-AC92-104588402193 Q27008325-DC5B51FE-04C6-41E2-9202-BA15BB597F65 Q28067491-E6D2BA99-0049-4DFB-99BA-93CA94E461A2 Q28075473-426742AF-B7D7-4DF6-A00F-9666ED2C0E7C Q28292764-2416D46A-9BAD-44CD-A2E7-1B14DA8FB6DD Q30101045-24F2B630-4FCB-45D3-A940-08B96BD176D7 Q31146850-CDADCC5D-497B-4D7A-B7F1-B24E135C2348 Q33606611-9A7128F9-7D01-45D0-8DFC-E2E884548F34 Q33740152-99004098-BE47-43D0-934B-C3BCCF91FAE1 Q33910289-B160C911-D2DF-4C7E-9744-9A549BD7BFD6 Q33912485-F027D0FB-7781-459B-BA93-D70D5B0B1120 Q34063072-7FFC1A5B-B1A5-4402-AF45-B74DA2A2EC25 Q34461573-AF24CA43-041B-47A3-A282-CE98554BAB74 Q34558187-ECBAEB11-9219-4A92-BD43-C9A761636CDB Q34693503-736ABA5D-FEB3-4C57-9F1C-8CA9F86C557F Q34711043-1898FE2E-E37F-4285-BFE9-81E567903416 Q34768919-2AC08603-4191-4BBF-A5B3-05EC4746FD6E Q34869372-48E5CB6A-4BA6-449C-9166-ADCF1241F7B0 Q35064343-62FAC601-524F-494F-BDB6-E5CA34452F6B Q35067102-3122E1A2-0F31-4F1C-9199-220679470529 Q35151008-5FEBE49A-6046-4240-98EE-C564B5D53C01 Q35171497-273E63E2-1117-4CCF-AF31-CC30D2AA7A63 Q35353446-0EA45573-D281-46B6-B4AB-1CB1FB084BAF Q35465478-A8179531-91E8-4A0B-890A-02E65BCC37DB Q35534298-A99253E2-D35E-405F-83DE-29D83A4C7E71 Q35568276-B9F96E2B-218B-4997-BE1E-F2C0C99E1736 Q35592307-8F80A98B-D3C3-4507-8362-B9F6C68992B7 Q35640797-D9F17BD0-9EFC-46BB-A640-F55D4C0F94FD Q35649512-BD845788-781F-4850-870E-3260A821303A Q35649815-DD9248EE-CF7B-49B7-9D29-A702AD575B50 Q35649867-0033B6E6-E559-478A-9003-C3F63CB1B543 Q35650268-60971B6E-2570-4793-B94E-B69D7FA51A72 Q35751912-A159CA9A-4779-45A7-9EFF-A2ED8DB83F8E Q35792895-8D33B3AA-F522-48E0-8C44-FF0B6C594115 Q35803183-8BA2668E-D08D-4355-A10A-CCB61D6A3297 Q35809696-FFD0E7ED-61D5-487B-B540-09CE6885080D

P2860

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

http://www.wikidata.org/entity/Q31100308

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Intravitreal ranibizumab for d ...... year randomized trial results.

@ast

Intravitreal ranibizumab for d ...... year randomized trial results.

@en

type

label

Intravitreal ranibizumab for d ...... year randomized trial results.

@ast

Intravitreal ranibizumab for d ...... year randomized trial results.

@en

prefLabel

Intravitreal ranibizumab for d ...... year randomized trial results.

@ast

Intravitreal ranibizumab for d ...... year randomized trial results.

@en

P1433

Q31100308-D7330663-CBAC-42D0-B72F-9F51E1AFE134

P1476

Q31100308-4F722E44-50C6-479C-B511-563D491FD37A

P2093

Q31100308-249E767F-1A85-40A9-B427-95EFCC9856F0

Q31100308-34917159-2CC4-42F4-A241-F3D9AEE86C18

Q31100308-611E5268-363C-44B3-8532-D4740D42B699

Q31100308-8256278B-C3EA-47F1-B3B9-D5EDDF12B92F

Q31100308-8CAFB507-2E78-4C90-873A-1525F1FE3554

Q31100308-98A800A3-6ED6-445B-A5C1-8D89C36CF3BF

Q31100308-9F5693E6-9BAE-41C3-8A1E-595CB4A37783

Q31100308-BB6AAD4F-3B11-4719-97DE-C0419736B85C

Q31100308-DEE49701-1360-4F04-B4F5-41CE578BA8B3

Q31100308-ED4B7C26-64EF-447A-8BF4-0F3A76903E4A

P2860

Q31100308-3B97F0FE-F356-4C89-9ECF-6250C11B20F1

Q31100308-86B684D8-38CB-4FB9-A154-AF717F08A2FC

Q31100308-CE58D9C4-1573-48AC-B0CA-6DF05873F273

P304

Q31100308-0A00BDE2-C6B1-4C5F-802B-AA9E81FAF12E

P31

Q31100308-D81EB85B-F441-45B6-A7FF-B5630551DA84

P356

Q31100308-AC45795E-1BD7-49DA-B6C7-6B9BD985F5D0

P433

Q31100308-65E36BB9-B63F-4271-ACC2-5396CF9A9BC1

P478

Q31100308-C8D3BB51-F26C-4E04-98FB-4379638D7A67

P577

Q31100308-1E2AB819-2DF7-420B-B595-D30C2A64686B

P5875

Q31100308-A7BCA387-3E00-40AF-B54B-B5FE6D222C8A

P698

Q31100308-DB8C5130-4BB5-437C-A178-1E8E85A94B46

P932

Q31100308-45A26260-6677-46D4-BE43-E0798C17AF8D

P356

J.OPHTHA.2012.08.022

P1433

P1476

Intravitreal ranibizumab for d ...... year randomized trial results.

@en

P2093

Adam R Glassman

http://www.w3.org/2001/XMLSchema#string

Diabetic Retinopathy Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

Haijing Qin

http://www.w3.org/2001/XMLSchema#string

Lloyd Paul Aiello

http://www.w3.org/2001/XMLSchema#string

Michael J Elman

http://www.w3.org/2001/XMLSchema#string

Michele Melia

http://www.w3.org/2001/XMLSchema#string

Neil M Bressler

http://www.w3.org/2001/XMLSchema#string

Raj K Maturi

http://www.w3.org/2001/XMLSchema#string

Roy W Beck

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

P304

2312-2318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2012.08.022

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256989428

http://www.w3.org/2001/XMLSchema#string

P698

22999634

http://www.w3.org/2001/XMLSchema#string

P932

3490003

http://www.w3.org/2001/XMLSchema#string